A detailed history of Pro Vise Management Group, LLC transactions in Eli Lilly & CO stock. As of the latest transaction made, Pro Vise Management Group, LLC holds 1,047 shares of LLY stock, worth $952,068. This represents 0.08% of its overall portfolio holdings.

Number of Shares
1,047
Previous 1,150 8.96%
Holding current value
$952,068
Previous $894,000 5.93%
% of portfolio
0.08%
Previous 0.08%

Shares

19 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

SELL
$724.87 - $909.04 $74,661 - $93,631
-103 Reduced 8.96%
1,047 $947,000
Q1 2024

May 09, 2024

SELL
$592.2 - $792.28 $200,163 - $267,790
-338 Reduced 22.72%
1,150 $894,000
Q4 2023

Feb 09, 2024

BUY
$525.19 - $619.13 $36,763 - $43,339
70 Added 4.94%
1,488 $867,000
Q3 2023

Nov 08, 2023

SELL
$434.7 - $599.3 $1.03 Million - $1.42 Million
-2,363 Reduced 62.5%
1,418 $761,000
Q2 2023

Aug 24, 2023

BUY
$350.74 - $468.98 $862,118 - $1.15 Million
2,458 Added 185.79%
3,781 $1.77 Million
Q1 2023

May 05, 2023

SELL
$310.63 - $364.82 $87,908 - $103,244
-283 Reduced 17.62%
1,323 $454,000
Q4 2022

Feb 09, 2023

BUY
$321.55 - $374.67 $283,285 - $330,084
881 Added 121.52%
1,606 $587,000
Q3 2022

Nov 09, 2022

SELL
$296.48 - $337.87 $26,979 - $30,746
-91 Reduced 11.15%
725 $235,000
Q2 2022

Aug 08, 2022

SELL
$278.73 - $327.27 $11,149 - $13,090
-40 Reduced 4.67%
816 $265,000
Q1 2022

Apr 27, 2022

BUY
$234.69 - $291.66 $18,305 - $22,749
78 Added 10.03%
856 $245,000
Q4 2021

Jan 18, 2022

BUY
$224.85 - $279.04 $174,933 - $217,093
778 New
778 $215,000
Q3 2021

Oct 20, 2021

SELL
$221.6 - $272.71 $221,378 - $272,437
-999 Closed
0 $0
Q2 2021

Aug 06, 2021

BUY
$180.55 - $233.54 $180,369 - $233,306
999 New
999 $229,000
Q4 2020

Jan 19, 2021

SELL
$130.46 - $172.63 $357,982 - $473,696
-2,744 Closed
0 $0
Q3 2020

Oct 26, 2020

BUY
$146.22 - $169.13 $134,814 - $155,937
922 Added 50.6%
2,744 $406,000
Q2 2020

Aug 07, 2020

BUY
$136.42 - $164.18 $248,557 - $299,135
1,822 New
1,822 $299,000
Q1 2019

May 13, 2019

SELL
$111.31 - $131.02 $452,141 - $532,203
-4,062 Closed
0 $0
Q2 2018

Aug 13, 2018

SELL
$75.7 - $86.88 $15,140 - $17,376
-200 Reduced 4.69%
4,062 $347,000
Q3 2017

Nov 08, 2017

BUY
$77.07 - $85.54 $328,472 - $364,571
4,262
4,262 $364,000

Others Institutions Holding LLY

About ELI LILLY & Co


  • Ticker LLY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 950,174,976
  • Market Cap $864B
  • Description
  • Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, T...
More about LLY
Track This Portfolio

Track Pro Vise Management Group, LLC Portfolio

Follow Pro Vise Management Group, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pro Vise Management Group, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pro Vise Management Group, LLC with notifications on news.